Loading viewer...
investor_presentation
Format: PDF investor_presentation
Capital management strategy Rafael Lizardi Senior vice president, chief financial officer Dave Pahl Vice president, head of investor relations February 5, 2019
Capital management strategy
Senior vice president, chief financial officer
Vice president, head of investor relations
February 5, 2019 2 Agenda for this call
* Free cash flow (FCF) = Cash flow from operations minus Capital expenditures •Capital management strategy and scorecard
•Historical view of our capital allocation
•R&D allocation priorities and results
•300mm Analog update
•Free cash flow* growth and outlook
3 Key takeaways from our discussion today
•We remain focused on consistent execution of our capital management strategy.
•Our business model is designed around four sustainable competitive advantages. We
invest with a long -term view to strengthen and leverage these competitive advantages.
•Our disciplined allocation of resources to R&D and our initiatives are delivering growth
in the best products (analog and embedded) and the best markets (industrial and
•Our 300mm Analog manufacturing strategy is a unique advantage and will provide
benefits for a long time.
•We remain committed to returning free cash flow to owners. 4
Maximize long -term growth of
free cash flow per share
1.Great business model: built around
four sustainable competitive advantages
2.Discipline: allocate capital to the
3.Efficiency: constantly strive for more
output per $ of input Capital management: objective and strategy Grow, generate and return
•TI is in a unique class of companies able to grow, generate and return cash to
shareholders for a long time to come.
•Focused on the best products and best markets within the semiconductor industry:
–Best products: analog and embedded – large, fragmented, used in everything electronic
‒Best markets: industrial and automotive – fastest growing due to increasing content
Preview truncated — download the full document for the complete content.
investor_presentation
10 Pages
Regeneron Pharmaceuticals, Inc.